Antiseptic Activity of Silver Nanoparticles Against E.Coli O157:H7
DOI:
https://doi.org/10.31580/pjmls.v4iSpecial%20Is.2177Keywords:
Silver nanoparticles (SNPs / AgNPs), E. coli (Escherichia coli), Hemolytic uremic syndrome (HUS)Abstract
Microorganisms resistant to numerous antimicrobial treatments have boosted demand for new disinfection technologies. There are many various types of antibacterial agents available, each with its own set of qualities; however, in order to achieve the intended antimicrobial effect, the correct disinfectant must be carefully selected for each application. Nanotechnology, including the use of substances with sizes on the atoms and molecules level, is gaining popularity in therapeutic diagnostics and is attracting a lot of attention as a way to kill or reduce the activity of a variety of bacteria. SNPs have been shown to have antiseptic effect beside nearly drug-resilient microorganisms. This review suggests that silver nanoparticles were tested for antibacterial efficacy against E. coli O157h7 and these tests imply that SNPs can be employed as actual progress restraint in a variety of bacteria, potentially making them useful in medical devices and antimicrobial control systems.
References
1. Dingman J. Guest commentary: nanotechnology: its impact on food safety. Journal of Environmental Health. 2008 1;70(6):47-50.
2. Da? C, Bezgin T, Özalp N. Dental management of patients with epidermolysis bullosa. Oral Health Dent Manag. 2014;13(3):623-7.
3. Brooks JK, Bare LC, Davidson J, Taylor LS, Wright JT. Junctional epidermolysis bullosa associated with hypoplastic enamel and pervasive failure of tooth eruption: Oral rehabilitation with use of an overdenture. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2008;105(4): e24-8.
4. Kampers FW. Opportunities for bionanotechnology in food and the food industry. Bionanotechnology: Global Prospects. 2008:79-90.
5. Rani K. Biomedical applications of silver and gold nanoparticles: effective and safe non-viral delivery vehicles. Journal of Applied Biotechnology and Bioengineering. 2017;3(2).
6. Sudrik SG, Chaki NK, Chavan VB, Chavan SP, Chavan SP, Sonawane HR, Vijayamohanan K. Silver nanocluster redox?couple?promoted nonclassical electron transfer: an efficient electrochemical wolff rearrangement of ??Diazoketones. Chemistry–A European Journal. 2006;12(3):859-64.
7. Dhanyalayam D, Scrivano L, Parisi OI, Sinicropi MS, Fazio A, Saturnino C, Plutino MR, Di Cristo F, Puoci F, Cappello AR, Longo P. Biopolymeric self-assembled nanoparticles for enhanced antibacterial activity of Ag-based compounds. International journal of pharmaceutics. 2017;517(1-2):395-402.
8. Neouze MA, Schubert U. Surface modification and functionalization of metal and metal oxide nanoparticles by organic ligands. Monatshefte für Chemie-Chemical Monthly. 2008;139(3):183-95.
9. Vilchis-Nestor AR, Sánchez-Mendieta V, Camacho-López MA, Gómez-Espinosa RM, Camacho-López MA, Arenas-Alatorre JA. Solventless synthesis and optical properties of Au and Ag nanoparticles using Camellia sinensis extract. Materials letters. 2008;62(17-18):3103-5.
10. Walser T, Demou E, Lang DJ, Hellweg S. Prospective environmental life cycle assessment of nanosilver T-shirts. Environmental science & technology. 2011;45(10):4570-8.
11. Yaktine A, Pray L, editors. Nanotechnology in food products: workshop summary. National Academies Press; 2009.
12. Berciaud S, Cognet L, Tamarat P, Lounis B. Observation of intrinsic size effects in the optical response of individual gold nanoparticles. Nano letters. 2005;5(3):515-8.
13. Alt V, Bechert T, Steinrücke P, Wagener M, Seidel P, Dingeldein E, Scheddin D, Domann E, Schnettler R. Nanopartikuläres Silber. Der Orthopäde. 2004;33(8):885-92.
14. Kossyrev PA, Yin A, Cloutier SG, Cardimona DA, Huang D, Alsing PM, Xu JM. Electric field tuning of plasmonic response of nanodot array in liquid crystal matrix. Nano letters. 2005;5(10):1978-81.
15. Luther EM, Koehler Y, Diendorf J, Epple M, Dringen R. Accumulation of silver nanoparticles by cultured primary brain astrocytes. Nanotechnology. 2011;22(37):375101.
16. Asharani PV, Hande MP, Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC cell biology. 2009;10(1):1-4.
17. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. Journal of Pharmacy and Bioallied Sciences. 2010;2(4):282.
18. Nowack B, Krug HF, Height M. 120 years of nanosilver history: implications for policy makers.
19. Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angewandte Chemie International Edition. 2013;52(6):1636-53.
20. Trickler WJ, Lantz SM, Murdock RC, Schrand AM, Robinson BL, Newport GD, Schlager JJ, Oldenburg SJ, Paule MG, Slikker Jr W, Hussain SM. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicological Sciences. 2010;118(1):160-70.
21. Liu W, Wu Y, Wang C, Li HC, Wang T, Liao CY, Cui L, Zhou QF, Yan B, Jiang GB. Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicology. 2010;4(3):319-30.
22. De M, Ghosh PS, Rotello VM. Applications of nanoparticles in biology. Advanced Materials. 2008 ;20(22):4225-41.
23. Jain P, Pradeep T. Potential of silver nanoparticle?coated polyurethane foam as an antibacterial water filter. Biotechnology and bioengineering. 2005;90(1):59-63.
24. Ghosh Chaudhuri R, Paria S. Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. Chemical reviews. 2012 ;112(4):2373-433.
25. Simon-Deckers A, Loo S, Mayne-L’hermite M, Herlin-Boime N, Menguy N, Reynaud C, Gouget B, Carriere M. Size-, composition-and shape-dependent toxicological impact of metal oxide nanoparticles and carbon nanotubes toward bacteria. Environmental science & technology. 2009 1;43(21):8423-9.
26. Murrell DF. Life with epidermolysis bullosa (EB): Etiology, diagnosis, multidisciplinary care and therapy. Journal of the American Academy of Dermatology. 2009;61(6):1092-3.
27. Kovacs S, Atasie D. Epidermolysis Bullosa–Review. Neonatology. 2012;2(11).
28. Gobert, R., Times change - A family story about living with E. e-bility.com. (2002).
29. Hinde, S., Little girl’s life of pain. HeraldSun.com.au. (2006).
30. Kim KJ, Sung WS, Moon SK, Choi JS, Kim JG, Lee DG. Antifungal effect of silver nanoparticles on dermatophytes. Journal of microbiology and biotechnology. 2008;18(8):1482-4.
31. Nadworny PL, Landry BK, Wang J, Tredget EE, Burrell RE. Does nanocrystalline silver have a transferable effect?. Wound repair and regeneration. 2010;18(2):254-65.
32. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. nature. 2000;407(6801):249-57.
33. Kim H, Choi JS, Kim KS, Yang JA, Joo CK, Hahn SK. Flt1 peptide–hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization. Acta biomaterialia. 2012;8(11):3932-40.
34. Baharara J, Namvar F, Mousavi M, Ramezani T, Mohamad R. Anti-angiogenesis effect of biogenic silver nanoparticles synthesized using saliva officinalis on chick chorioalantoic membrane (CAM). Molecules. 2014;19(9):13498-508.
35. Gopinath P, Gogoi SK, Chattopadhyay A, Ghosh SS. Implications of silver nanoparticle induced cell apoptosis for in vitro gene therapy. Nanotechnology. 2008;19(7):075104.
36. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual review of biomedical engineering. 2012;14:1-6.
37. Benn TM, Westerhoff P. Nanoparticle silver released into water from commercially available sock fabrics. Environmental science & technology. 2008;42(11):4133-9.
38. Nadworny PL, Wang J, Tredget EE, Burrell RE. Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Nanomedicine: nanotechnology, biology and medicine. 2008 ;4(3):241-51.
39. Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. American journal of infection control. 1999;27(4):344-50.
40. Rogers JV, Parkinson CV, Choi YW, Speshock JL, Hussain SM. A preliminary assessment of silver nanoparticle inhibition of monkeypox virus plaque formation. Nanoscale Research Letters. 2008;3(4):129-33.
41. Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clinics in dermatology. 2012;30(1):70-7.
42. Krutyakov YA, Kudrinskiy AA, Olenin AY, Lisichkin GV. Synthesis and properties of silver nanoparticles: advances and prospects. Russian Chemical Reviews. 2008;77(3):233.
43. Monteiro DR, Gorup LF, Takamiya AS, Ruvollo-Filho AC, de Camargo ER, Barbosa DB. The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medical devices containing silver. International journal of antimicrobial agents. 2009;34(2):103-10.
44. McGrath JA. Recently identified forms of epidermolysis bullosa. Annals of dermatology. 2015;27(6):658-66.
45. García-Barrasa J, López-de-Luzuriaga JM, Monge M. Silver nanoparticles: synthesis through chemical methods in solution and biomedical applications. Central European journal of chemistry. 2011;9(1):7-19.
46. Dallas P, Sharma VK, Zboril R. Silver polymeric nanocomposites as advanced antimicrobial agents: classification, synthetic paths, applications, and perspectives. Advances in colloid and interface science. 2011;166(1-2):119-35.
47. Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. Journal of the American Academy of Dermatology. 2008;58(6):931-50.
48. Momeni, A., and K. Pieper. "Junctional epidermolysis bullosa: a case report." International journal of paediatric dentistry. 2005;15(2): 146-150.
49. Gurr JR, Wang AS, Chen CH, Jan KY. Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology. 2005;213(1-2):66-73.
50. Cogan TA, Slader J, Bloomfield SF, Humphrey TJ. Achieving hygiene in the domestic kitchen: the effectiveness of commonly used cleaning procedures. Journal of Applied Microbiology. 2002;92(5):885-92.
51. Oliveira TM, Sakai VT, Candido LA, Silva S, Machado MA. Clinical management for epidermolysis bullosa dystrophica. Journal of Applied Oral Science. 2008;16(1):81-5.
52. Boeira VL, Souza ES, Rocha BD, Oliveira PD, Oliveira MD, Rêgo VR, Follador I. Inherited epidermolysis bullosa: clinical and therapeutic aspects. Anais brasileiros de dermatologia. 2013; 88:185-98.
53. Al-Qadiri HM, Lin M, Cavinato AG, Rasco BA. Fourier transform infrared spectroscopy, detection and identification of Escherichia coli O157: H7 and Alicyclobacillus strains in apple juice. International journal of food microbiology. 2006;111(1):73-80.
54. Al-Holy MA, Lin M, Cavinato AG, Rasco BA. The use of Fourier transform infrared spectroscopy to differentiate Escherichia coli O157: H7 from other bacteria inoculated into apple juice. Food microbiology. 2006;23(2):162-8.
55. Shinkuma S, McMillan JR, Shimizu H. Ultrastructure and molecular pathogenesis of epidermolysis bullosa. Clinics in dermatology. 2011;29(4):412-9.
56. Mitsuhashi Y, Hashimoto I. Genetic abnormalities and clinical classification of epidermolysis bullosa. Archives of dermatological research. 2003;295(1): S29-33.
57. Bolling MC, Lemmink HH, Jansen GH, Jonkman MF. Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients. British Journal of Dermatology. 2011;164(3):637-44.
58. Sprecher E. Epidermolysis bullosa simplex. Dermatologic clinics. 2010;28(1):23-32.
59. Almaani N, Liu L, Dopping?Hepenstal PJ, Lovell PA, Lai?Cheong JE, Graham RM, Mellerio JE, McGrath JA. Autosomal dominant junctional epidermolysis bullosa. British Journal of Dermatology. 2009;160(5):1094-7.
60. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. Journal of the American Academy of Dermatology. 2009;61(3):367-84.
61. Lai-Cheong JE, McGrath JA. Kindler syndrome. Dermatologic clinics. 2010;28(1):119-24.
62. Ashton GH, McLean WI, South AP, Oyama N, Smith FJ, Al-Suwaid R, Al Ismaily A, Atherton DJ, Harwood CA, Leigh IM, Moss C. Recurrent mutations in kindlin-1, a novel keratinocyte focal contact protein, in the autosomal recessive skin fragility and photosensitivity disorder, Kindler syndrome. Journal of investigative dermatology. 2004;122(1):78-83.
63. Shah K, Mehmood S, Jan A, Abbe I, Hussain Ali R, Khan A, Chishti MS, Lee K, Ahmad F, Ansar M, University of Washington Center for Mendelian Genomics. Sequence variants in nine different genes underlying rare skin disorders in 10 consanguineous families. International journal of dermatology. 2017;56(12):1406-13.
64. Kivirikko S, McGrath JA, Pulkkinen L, Uitto J, Christiano AM. Mutational hotspots in the LAMB3 gene in the lethal (Herlitz) type of junctional epidermolysis bullosa. Human molecular genetics. 1996;5(2):231-7.
65. Bhinder MA, Arshad MW, Zahoor MY, Shehzad W, Tariq M, Shabbir MI. Junctional epidermolysis bullosa (non-Herlitz type). J Coll Physicians Surg Pak. 2017; 27:308-10.
66. Nazir Z, Attar ZB, Moazam F. Congenital pyloric atresia and epidermolysis bullosa. Journal of the Pakistan Medical Association. 1991;41(10):254.
67. Pfendner E, Uitto J. Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. Journal of investigative dermatology. 2005;124(1):111-5.
68. Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clinics in dermatology. 2012;30(1):60-9.
69. Mohammad N, Sohaila A, Hussain AA, Ani S. Epidermolysis Bullosa in the Newborn. Journal of Ayub Medical College Abbottabad. 2016;28(1):186-8.
70. Roy R, Hoover MR, Bhalla AS, Slawecki T, Dey S, Cao W, Li J, Bhaskar S. Ultradilute Ag-aquasols with extraordinary bactericidal properties: role of the system Ag–O–H2O. Materials Research Innovations. 2007;11(1):3-18.
71. Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatologic clinics. 2010;28(1):159.
72. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. Journal of colloid and interface science. 2004 Jul 1;275(1):177-82.
73. Tosti A, Duque-Estrada B, Murrell DF. Alopecia in epidermolysis bullosa. Dermatologic clinics. 2010;28(1):165-9.
74. Fine JD. Inherited epidermolysis bullosa. Orphanet journal of rare diseases. 2010 Dec;5(1):1-7.
75. Yuen WY, Duipmans JC, Molenbuur B, Herpertz I, Mandema JM, Jonkman MF. Long?term follow?up of patients with Herlitz?type junctional epidermolysis bullosa. British Journal of Dermatology. 2012;167(2):374-82.
76. Horn HM, Tidman MJ. The clinical spectrum of dystrophic epidermolysis bullosa. British Journal of Dermatology. 2002;146(2):267-74.
77. Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: pathogenesis and clinical features. Dermatologic clinics. 2010;28(1):107-14.
78. Hussain R, Bittles AH. The prevalence and demographic characteristics of consanguineous marriages in Pakistan. Journal of biosocial science. 1998;30(2):261-75.
79. Hamamy H. Consanguineous marriages. Journal of community genetics. 2012;3(3):185-92.
80. McGrath JA, Kivirikko S, Ciatti S, Moss C, Christiano AM, Uitto J. A recurrent homozygous nonsense mutation within the LAMA3 gene as a cause of Herlitz junctional epidermolysis bullosa in patients of Pakistani ancestry: evidence for a founder effect. Journal of investigative dermatology. 1996;106(4).
2. Da? C, Bezgin T, Özalp N. Dental management of patients with epidermolysis bullosa. Oral Health Dent Manag. 2014;13(3):623-7.
3. Brooks JK, Bare LC, Davidson J, Taylor LS, Wright JT. Junctional epidermolysis bullosa associated with hypoplastic enamel and pervasive failure of tooth eruption: Oral rehabilitation with use of an overdenture. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2008;105(4): e24-8.
4. Kampers FW. Opportunities for bionanotechnology in food and the food industry. Bionanotechnology: Global Prospects. 2008:79-90.
5. Rani K. Biomedical applications of silver and gold nanoparticles: effective and safe non-viral delivery vehicles. Journal of Applied Biotechnology and Bioengineering. 2017;3(2).
6. Sudrik SG, Chaki NK, Chavan VB, Chavan SP, Chavan SP, Sonawane HR, Vijayamohanan K. Silver nanocluster redox?couple?promoted nonclassical electron transfer: an efficient electrochemical wolff rearrangement of ??Diazoketones. Chemistry–A European Journal. 2006;12(3):859-64.
7. Dhanyalayam D, Scrivano L, Parisi OI, Sinicropi MS, Fazio A, Saturnino C, Plutino MR, Di Cristo F, Puoci F, Cappello AR, Longo P. Biopolymeric self-assembled nanoparticles for enhanced antibacterial activity of Ag-based compounds. International journal of pharmaceutics. 2017;517(1-2):395-402.
8. Neouze MA, Schubert U. Surface modification and functionalization of metal and metal oxide nanoparticles by organic ligands. Monatshefte für Chemie-Chemical Monthly. 2008;139(3):183-95.
9. Vilchis-Nestor AR, Sánchez-Mendieta V, Camacho-López MA, Gómez-Espinosa RM, Camacho-López MA, Arenas-Alatorre JA. Solventless synthesis and optical properties of Au and Ag nanoparticles using Camellia sinensis extract. Materials letters. 2008;62(17-18):3103-5.
10. Walser T, Demou E, Lang DJ, Hellweg S. Prospective environmental life cycle assessment of nanosilver T-shirts. Environmental science & technology. 2011;45(10):4570-8.
11. Yaktine A, Pray L, editors. Nanotechnology in food products: workshop summary. National Academies Press; 2009.
12. Berciaud S, Cognet L, Tamarat P, Lounis B. Observation of intrinsic size effects in the optical response of individual gold nanoparticles. Nano letters. 2005;5(3):515-8.
13. Alt V, Bechert T, Steinrücke P, Wagener M, Seidel P, Dingeldein E, Scheddin D, Domann E, Schnettler R. Nanopartikuläres Silber. Der Orthopäde. 2004;33(8):885-92.
14. Kossyrev PA, Yin A, Cloutier SG, Cardimona DA, Huang D, Alsing PM, Xu JM. Electric field tuning of plasmonic response of nanodot array in liquid crystal matrix. Nano letters. 2005;5(10):1978-81.
15. Luther EM, Koehler Y, Diendorf J, Epple M, Dringen R. Accumulation of silver nanoparticles by cultured primary brain astrocytes. Nanotechnology. 2011;22(37):375101.
16. Asharani PV, Hande MP, Valiyaveettil S. Anti-proliferative activity of silver nanoparticles. BMC cell biology. 2009;10(1):1-4.
17. Mody VV, Siwale R, Singh A, Mody HR. Introduction to metallic nanoparticles. Journal of Pharmacy and Bioallied Sciences. 2010;2(4):282.
18. Nowack B, Krug HF, Height M. 120 years of nanosilver history: implications for policy makers.
19. Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angewandte Chemie International Edition. 2013;52(6):1636-53.
20. Trickler WJ, Lantz SM, Murdock RC, Schrand AM, Robinson BL, Newport GD, Schlager JJ, Oldenburg SJ, Paule MG, Slikker Jr W, Hussain SM. Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicological Sciences. 2010;118(1):160-70.
21. Liu W, Wu Y, Wang C, Li HC, Wang T, Liao CY, Cui L, Zhou QF, Yan B, Jiang GB. Impact of silver nanoparticles on human cells: effect of particle size. Nanotoxicology. 2010;4(3):319-30.
22. De M, Ghosh PS, Rotello VM. Applications of nanoparticles in biology. Advanced Materials. 2008 ;20(22):4225-41.
23. Jain P, Pradeep T. Potential of silver nanoparticle?coated polyurethane foam as an antibacterial water filter. Biotechnology and bioengineering. 2005;90(1):59-63.
24. Ghosh Chaudhuri R, Paria S. Core/shell nanoparticles: classes, properties, synthesis mechanisms, characterization, and applications. Chemical reviews. 2012 ;112(4):2373-433.
25. Simon-Deckers A, Loo S, Mayne-L’hermite M, Herlin-Boime N, Menguy N, Reynaud C, Gouget B, Carriere M. Size-, composition-and shape-dependent toxicological impact of metal oxide nanoparticles and carbon nanotubes toward bacteria. Environmental science & technology. 2009 1;43(21):8423-9.
26. Murrell DF. Life with epidermolysis bullosa (EB): Etiology, diagnosis, multidisciplinary care and therapy. Journal of the American Academy of Dermatology. 2009;61(6):1092-3.
27. Kovacs S, Atasie D. Epidermolysis Bullosa–Review. Neonatology. 2012;2(11).
28. Gobert, R., Times change - A family story about living with E. e-bility.com. (2002).
29. Hinde, S., Little girl’s life of pain. HeraldSun.com.au. (2006).
30. Kim KJ, Sung WS, Moon SK, Choi JS, Kim JG, Lee DG. Antifungal effect of silver nanoparticles on dermatophytes. Journal of microbiology and biotechnology. 2008;18(8):1482-4.
31. Nadworny PL, Landry BK, Wang J, Tredget EE, Burrell RE. Does nanocrystalline silver have a transferable effect?. Wound repair and regeneration. 2010;18(2):254-65.
32. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. nature. 2000;407(6801):249-57.
33. Kim H, Choi JS, Kim KS, Yang JA, Joo CK, Hahn SK. Flt1 peptide–hyaluronate conjugate micelle-like nanoparticles encapsulating genistein for the treatment of ocular neovascularization. Acta biomaterialia. 2012;8(11):3932-40.
34. Baharara J, Namvar F, Mousavi M, Ramezani T, Mohamad R. Anti-angiogenesis effect of biogenic silver nanoparticles synthesized using saliva officinalis on chick chorioalantoic membrane (CAM). Molecules. 2014;19(9):13498-508.
35. Gopinath P, Gogoi SK, Chattopadhyay A, Ghosh SS. Implications of silver nanoparticle induced cell apoptosis for in vitro gene therapy. Nanotechnology. 2008;19(7):075104.
36. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual review of biomedical engineering. 2012;14:1-6.
37. Benn TM, Westerhoff P. Nanoparticle silver released into water from commercially available sock fabrics. Environmental science & technology. 2008;42(11):4133-9.
38. Nadworny PL, Wang J, Tredget EE, Burrell RE. Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model. Nanomedicine: nanotechnology, biology and medicine. 2008 ;4(3):241-51.
39. Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. American journal of infection control. 1999;27(4):344-50.
40. Rogers JV, Parkinson CV, Choi YW, Speshock JL, Hussain SM. A preliminary assessment of silver nanoparticle inhibition of monkeypox virus plaque formation. Nanoscale Research Letters. 2008;3(4):129-33.
41. Intong LR, Murrell DF. Inherited epidermolysis bullosa: new diagnostic criteria and classification. Clinics in dermatology. 2012;30(1):70-7.
42. Krutyakov YA, Kudrinskiy AA, Olenin AY, Lisichkin GV. Synthesis and properties of silver nanoparticles: advances and prospects. Russian Chemical Reviews. 2008;77(3):233.
43. Monteiro DR, Gorup LF, Takamiya AS, Ruvollo-Filho AC, de Camargo ER, Barbosa DB. The growing importance of materials that prevent microbial adhesion: antimicrobial effect of medical devices containing silver. International journal of antimicrobial agents. 2009;34(2):103-10.
44. McGrath JA. Recently identified forms of epidermolysis bullosa. Annals of dermatology. 2015;27(6):658-66.
45. García-Barrasa J, López-de-Luzuriaga JM, Monge M. Silver nanoparticles: synthesis through chemical methods in solution and biomedical applications. Central European journal of chemistry. 2011;9(1):7-19.
46. Dallas P, Sharma VK, Zboril R. Silver polymeric nanocomposites as advanced antimicrobial agents: classification, synthetic paths, applications, and perspectives. Advances in colloid and interface science. 2011;166(1-2):119-35.
47. Fine JD, Eady RA, Bauer EA, Bauer JW, Bruckner-Tuderman L, Heagerty A, Hintner H, Hovnanian A, Jonkman MF, Leigh I, McGrath JA. The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. Journal of the American Academy of Dermatology. 2008;58(6):931-50.
48. Momeni, A., and K. Pieper. "Junctional epidermolysis bullosa: a case report." International journal of paediatric dentistry. 2005;15(2): 146-150.
49. Gurr JR, Wang AS, Chen CH, Jan KY. Ultrafine titanium dioxide particles in the absence of photoactivation can induce oxidative damage to human bronchial epithelial cells. Toxicology. 2005;213(1-2):66-73.
50. Cogan TA, Slader J, Bloomfield SF, Humphrey TJ. Achieving hygiene in the domestic kitchen: the effectiveness of commonly used cleaning procedures. Journal of Applied Microbiology. 2002;92(5):885-92.
51. Oliveira TM, Sakai VT, Candido LA, Silva S, Machado MA. Clinical management for epidermolysis bullosa dystrophica. Journal of Applied Oral Science. 2008;16(1):81-5.
52. Boeira VL, Souza ES, Rocha BD, Oliveira PD, Oliveira MD, Rêgo VR, Follador I. Inherited epidermolysis bullosa: clinical and therapeutic aspects. Anais brasileiros de dermatologia. 2013; 88:185-98.
53. Al-Qadiri HM, Lin M, Cavinato AG, Rasco BA. Fourier transform infrared spectroscopy, detection and identification of Escherichia coli O157: H7 and Alicyclobacillus strains in apple juice. International journal of food microbiology. 2006;111(1):73-80.
54. Al-Holy MA, Lin M, Cavinato AG, Rasco BA. The use of Fourier transform infrared spectroscopy to differentiate Escherichia coli O157: H7 from other bacteria inoculated into apple juice. Food microbiology. 2006;23(2):162-8.
55. Shinkuma S, McMillan JR, Shimizu H. Ultrastructure and molecular pathogenesis of epidermolysis bullosa. Clinics in dermatology. 2011;29(4):412-9.
56. Mitsuhashi Y, Hashimoto I. Genetic abnormalities and clinical classification of epidermolysis bullosa. Archives of dermatological research. 2003;295(1): S29-33.
57. Bolling MC, Lemmink HH, Jansen GH, Jonkman MF. Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients. British Journal of Dermatology. 2011;164(3):637-44.
58. Sprecher E. Epidermolysis bullosa simplex. Dermatologic clinics. 2010;28(1):23-32.
59. Almaani N, Liu L, Dopping?Hepenstal PJ, Lovell PA, Lai?Cheong JE, Graham RM, Mellerio JE, McGrath JA. Autosomal dominant junctional epidermolysis bullosa. British Journal of Dermatology. 2009;160(5):1094-7.
60. Fine JD, Mellerio JE. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. Journal of the American Academy of Dermatology. 2009;61(3):367-84.
61. Lai-Cheong JE, McGrath JA. Kindler syndrome. Dermatologic clinics. 2010;28(1):119-24.
62. Ashton GH, McLean WI, South AP, Oyama N, Smith FJ, Al-Suwaid R, Al Ismaily A, Atherton DJ, Harwood CA, Leigh IM, Moss C. Recurrent mutations in kindlin-1, a novel keratinocyte focal contact protein, in the autosomal recessive skin fragility and photosensitivity disorder, Kindler syndrome. Journal of investigative dermatology. 2004;122(1):78-83.
63. Shah K, Mehmood S, Jan A, Abbe I, Hussain Ali R, Khan A, Chishti MS, Lee K, Ahmad F, Ansar M, University of Washington Center for Mendelian Genomics. Sequence variants in nine different genes underlying rare skin disorders in 10 consanguineous families. International journal of dermatology. 2017;56(12):1406-13.
64. Kivirikko S, McGrath JA, Pulkkinen L, Uitto J, Christiano AM. Mutational hotspots in the LAMB3 gene in the lethal (Herlitz) type of junctional epidermolysis bullosa. Human molecular genetics. 1996;5(2):231-7.
65. Bhinder MA, Arshad MW, Zahoor MY, Shehzad W, Tariq M, Shabbir MI. Junctional epidermolysis bullosa (non-Herlitz type). J Coll Physicians Surg Pak. 2017; 27:308-10.
66. Nazir Z, Attar ZB, Moazam F. Congenital pyloric atresia and epidermolysis bullosa. Journal of the Pakistan Medical Association. 1991;41(10):254.
67. Pfendner E, Uitto J. Plectin gene mutations can cause epidermolysis bullosa with pyloric atresia. Journal of investigative dermatology. 2005;124(1):111-5.
68. Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clinics in dermatology. 2012;30(1):60-9.
69. Mohammad N, Sohaila A, Hussain AA, Ani S. Epidermolysis Bullosa in the Newborn. Journal of Ayub Medical College Abbottabad. 2016;28(1):186-8.
70. Roy R, Hoover MR, Bhalla AS, Slawecki T, Dey S, Cao W, Li J, Bhaskar S. Ultradilute Ag-aquasols with extraordinary bactericidal properties: role of the system Ag–O–H2O. Materials Research Innovations. 2007;11(1):3-18.
71. Wright JT. Oral manifestations in the epidermolysis bullosa spectrum. Dermatologic clinics. 2010;28(1):159.
72. Sondi I, Salopek-Sondi B. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. Journal of colloid and interface science. 2004 Jul 1;275(1):177-82.
73. Tosti A, Duque-Estrada B, Murrell DF. Alopecia in epidermolysis bullosa. Dermatologic clinics. 2010;28(1):165-9.
74. Fine JD. Inherited epidermolysis bullosa. Orphanet journal of rare diseases. 2010 Dec;5(1):1-7.
75. Yuen WY, Duipmans JC, Molenbuur B, Herpertz I, Mandema JM, Jonkman MF. Long?term follow?up of patients with Herlitz?type junctional epidermolysis bullosa. British Journal of Dermatology. 2012;167(2):374-82.
76. Horn HM, Tidman MJ. The clinical spectrum of dystrophic epidermolysis bullosa. British Journal of Dermatology. 2002;146(2):267-74.
77. Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: pathogenesis and clinical features. Dermatologic clinics. 2010;28(1):107-14.
78. Hussain R, Bittles AH. The prevalence and demographic characteristics of consanguineous marriages in Pakistan. Journal of biosocial science. 1998;30(2):261-75.
79. Hamamy H. Consanguineous marriages. Journal of community genetics. 2012;3(3):185-92.
80. McGrath JA, Kivirikko S, Ciatti S, Moss C, Christiano AM, Uitto J. A recurrent homozygous nonsense mutation within the LAMA3 gene as a cause of Herlitz junctional epidermolysis bullosa in patients of Pakistani ancestry: evidence for a founder effect. Journal of investigative dermatology. 1996;106(4).
Downloads
Published
2022-04-30
